Squarepoint
ABUS icon

Squarepoint’s Arbutus Biopharma ABUS Stock Holding History

Squarepoint’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-28,775
Closed -$138K – 4192
2025
Q4 		$138K Sell
28,775
-38,836
-57% -$175K ﹤0.01% 3969
2025
Q3 		$307K Buy
67,611
+43,801
+184% +$161K ﹤0.01% 3649
2025
Q2 		$73.6K Buy
23,810
+6,454
+37% +$21.4K ﹤0.01% 4242
2025
Q1 		$60.6K Sell
17,356
-160,743
-90% -$536K ﹤0.01% 4314
2024
Q4 		$582K Buy
178,099
+113,291
+175% +$417K ﹤0.01% 3604
2024
Q3 		$250K Buy
+64,808
New +$249K ﹤0.01% 3567
2023
Q1 		– Sell
-13,650
Closed -$31.8K – 3165
2022
Q4 		$31.8K Buy
+13,650
New +$32.7K ﹤0.01% 3087
2022
Q1 		– Sell
-40,014
Closed -$156K – 2742
2021
Q4 		$156K Buy
+40,014
New +$155K ﹤0.01% 2800
2021
Q2 		– Sell
-29,880
Closed -$100K – 3161
2021
Q1 		$100K Buy
+29,880
New +$115K ﹤0.01% 2907
2020
Q3 		– Sell
-322,225
Closed -$586K – 2439
2020
Q2 		$586K Buy
322,225
+279,982
+663% +$458K 0.01% 1222
2020
Q1 		$43K Buy
+42,243
New +$114K ﹤0.01% 1729
2019
Q3 		– Sell
-65,848
Closed -$137K – 2298
2019
Q2 		$137K Buy
+65,848
New +$168K ﹤0.01% 2176
2018
Q2 		– Sell
-13,300
Closed -$67K – 1715
2018
Q1 		$67K Sell
13,300
-300
-2% -$1.59K ﹤0.01% 1602
2017
Q4 		$69K Buy
13,600
+3,300
+32% +$19.3K ﹤0.01% 1995
2017
Q3 		$64K Buy
+10,300
New +$44.1K ﹤0.01% 1549
2017
Q1 		– Sell
-13,400
Closed -$33K – 1482
2016
Q4 		$33K Buy
+13,400
New +$39K ﹤0.01% 1716

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Squarepoint's ABUS Position: Q1 2026 in Review

Squarepoint sold out of Arbutus Biopharma (ABUS) in Q1 2026, closing a stake of 28,775 shares — an estimated $138K sold.

Squarepoint first reported a position in ABUS in Q4 2016 and held it in 16 quarters. The position peaked at $586K in Q2 2020. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Squarepoint reported no remaining Arbutus Biopharma position as of Q1 2026 after selling out during the quarter.
  • Squarepoint sold 28,775 Arbutus Biopharma shares in Q1 2026, an estimated $138K.
  • Squarepoint first reported a position in Arbutus Biopharma in Q4 2016 and held it in 16 quarters.
  • Squarepoint's Arbutus Biopharma position peaked at $586K in Q2 2020.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.